Validation and development of RP-HPLC method for quantification of glibenclamide in rat plasma and its application to pharmacokinetic studies in wistar rats

• Published in: Heliyon 2023-11, Vol.9 (11), p.e20876-e20876, Article e20876
• Main Authors: Mir, Khalid Bashir, Abrol, Vidushi, Wani, Taha U., Jan, Ishrat, Singh, Nasseb, Khan, Nisar A., Dar, Alamgir A., Sabri Sultan, Rania Mohammad, Lone, Showkat A., Iesa, Mohamed A.M., Alhag, Sadeq K., Al-Shuraym, Laila A., Helm, Nawal, AL-Farga, Ammar
• Format: Article
• Language: English
• Subjects: Glibenclamide; Method validation; Pharmacokinetics; Plasma; RP-HPLC; Wistar rats
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2023.e20876

Herein, we report a novel, simple, specific, accurate and cost-friendly validated reverse phase-high performance liquid chromatographic (RP-HPLC) method for the quantification of second generation sulphonylurea based antidiabetic drug, glibenclamide (GLB) in rat plasma and its application to calculate pharmacokinetic parameters in wistar rats. The internal standard used was flufenamic acid. The chromatographic separation was conducted on C18 column (250 mm × 4.6 mm x 5 μm, Agilent-Zorbax, SB) using isocratic elution with mobile phase containing Acetonitrile: Water (1:1; v/v) pH adjusted to 4.0 with 0.03 % glacial acetic acid and detected by photo-diode array as detector. Calibration curves made in the rat plasma were linear in the range of 50–1200 ng/ml with r2 = 0.998. The LLOQ was 40 ng/ml. This method was effectively applied for pharmacokinetic studies of Glibenclamide following administration through oral route as solid dispersion formulation to Wistar rats. Several methods are available in the literature which can be employed for the quantification of Glibenclamide but such methods are tedious, provide lower sensitivity, less simultaneous resolution and are time-consuming. Therefore the present methods suits best for the quantification of Glibenclamide from Wistar rats.